ArticleClinical and translational medicine2026
RNA binding protein ZFP36L1 promotes ferroptosis in chronic rhinosinusitis by destabilizing CAMK2A mRNA and impairing mitochondrial quality control.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRNA-binding proteins (RBPs) and ferroptosis have been demonstrated to play important roles in the progression of chronic rhinosinusitis (CRS). However, the regulatory mechanisms underlying the interaction between RBPs and ferroptosis in CRS, particularly regarding mitochondrial metabolism, remain elusive.
methodsHub genes correlated with RBP-related genes, ferroptosis-related genes and mitochondrial-related genes were identified by integrated bioinformatics analysis. CRS in vivo models were constructed, clinical samples were collected, and mechanistic analyses were performed for validation.
resultsZFP36L1 was identified as the hub gene associated with CRS development. In vivo experiments demonstrated that ZFP36L1 directly binds to the 3'-untranslated region of CAMK2A mRNA and promotes its degradation through AU-rich element recognition. ZFP36L1 knockout in CRS mouse models restored CAMK2A expression and significantly attenuated ferroptosis markers, reactive oxygen species accumulation and mitochondrial dysfunction. Rescue experiments revealed that CAMK2A knockdown reversed the protective effects of ZFP36L1 depletion on ferroptosis and mitochondrial quality control. Clinical samples confirmed that ZFP36L1 expression was inversely correlated with CAMK2A levels, and both were associated with disease severity.
conclusionThis study identifies ZFP36L1-CAMK2A as a contributory regulatory mechanism in CRS pathogenesis. ZFP36L1 promotes ferroptosis by destabilizing CAMK2A mRNA, leading to mitochondrial dysfunction and subsequent epithelial cell death. These findings provide new mechanistic insights into CRS progression and identify potential therapeutic targets. HIGHLIGHTS: ZFP36L1 is identified as a key driver gene in chronic rhinosinusitis (CRS) progression via integrated bioinformatics analysis. ZFP36L1 promotes ferroptosis by binding to and destabilizing CAMK2A mRNA through AU-rich elements in its 3'-UTR. Genetic knockout of ZFP36L1 attenuates ferroptosis and restores mitochondrial quality control in CRS models. Clinical validation confirms the ZFP36L1-CAMK2A axis correlates with disease severity and represents a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.